© 2020 MJH Life Sciences and OncLive. All rights reserved.
April 22, 2020
James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.
April 10, 2020
James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.
February 27, 2020
James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.
February 22, 2020